Search
Elicio Therapeutics Inc
ELTXAdd to Watchlist
1.870USD
-0.040-2.09%
Close 09-21 16:00（ET）
41.39MMarket Cap
LossP/E TTM
Elicio Therapeutics Inc (ELTX) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Elicio Therapeutics Inc in the past month.
Buy
1 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
20.000USD+958.20%
ELTX Analyst Recommendation Trends
In the current month, ELTX has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ELTX average Analyst price target in the last month is 20.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
0
0
0
0
0
0
2
2
2
2
2
2
2
2
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
2
2
2
2
2
2
ELTX Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, ELTX EPS is projected to reach -0.480 in FY2026Q3, following reported EPS of -0.427 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.45
-0.47
-0.54
-0.48
-0.46
Actual
-0.50
-0.65
-0.43
--
--
Surprise
-11.84%
-39.61%
+20.49%
--
--
FAQs
What is Elicio Therapeutics Inc's price target?
Analysts forecast that Elicio Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 27.00 and the lowest forecast at USD 10.00.
How have Elicio Therapeutics IncELTX's recent earnings per share performed?
The market expectation was USD -0.43, while Elicio Therapeutics IncELTX's earnings per share (EPS) for the previous quarter was USD -0.65. EPS for the next quarter is expected at USD -0.48.
What is the analyst rating for Elicio Therapeutics Inc?
Based on the ratings of Elicio Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.